Eisai Seeks Accelerated Approval for Alzheimer’s Drug Lecanemab
By
Simon Spichak
| September 28th, 2021
Eisai’s investigational Alzheimer’s drug lecanemab appeared to erase amyloid plaques in 4/5 of trial participants and slow cognitive decline for people with early-stage Alzheimer’s…